Eurofins · 8 hours ago
Cell Gene Therapy Scientist
Malvern, PA, USA
Full-time
Onsite
Mid Level
3+ years expEurofins is an international life sciences company providing analytical testing services to ensure the safety and authenticity of products. They are seeking a Cell Gene Therapy Scientist to perform cell culture, assist in method development, and maintain laboratory records.
BiotechnologyGeneticsHealth CareLife SciencePharmaceutical
No H1B
Responsibilities
Perform mammalian cell culture passaging/ splitting, continuous maintenance, & cell counting
Use micro pipettes for precise readings in cell-based assays & plate-based assays (ELISA, Alphalisa)
Use qPCR, dPCR, DNA isolations and sequencing
Maintain electronic lab notebooks & GMP complaint record keeping
Work on new method development as well as optimize existing methods
Successful candidates are adaptable/flexible to dynamic method development settings, to accommodate quick changes in protocols
Qualification
Required
Completed Bachelors or Masters degree in scientific concentration, PhD is preferred
3+ years of industry experience
Experience required with Mammalian cell culture
Experience required with PCR, qPCR, d PCR, dd PCR
Experience required with DNA isolation
Experience required with Plate based assays, ELISA, MSD
Experience required with Western blot, SDS silver staining, SDS PAGE, gel electrophoresis
Maintain electronic lab notebooks & GMP complaint record keeping
Work on new method development as well as optimize existing methods
Flexible to dynamic method development settings, to accommodate quick changes in protocols
Authorization to work in the United States indefinitely without restrictions or sponsorship
Benefits
Excellent full time benefits including comprehensive medical coverage, dental, and vision options
Life and disability insurance
401(k) with company match
Paid vacation and holidays
Company
Eurofins
Eurofins provides testing and support services to the pharmaceutical, food, environmental, and consumer products industries.
10001+ employees
Funding
Current Stage
Public CompanyTotal Funding
$1.05B2025-06-26Post Ipo Debt· $586.37M
2025-03-27Post Ipo Debt· $431.4M
2021-10-22Grant· $30M
Leadership Team
C
Cara Ahern
Documentation Specialist
Yves-Loic Martin
Board Member
Recent News
2025-12-16
Business Wire
2025-12-08
Company data provided by crunchbase